A randomized, open-label, multicenter comparative trial of levetiracetam and topiramate as adjunctive treatment for patients with focal epilepsy in Korea.

CONCLUSIONS: In this open-label trial, the 52-week retention rate was not significantly different between LEV and TPM. However, LEV was associated with a substantially higher seizure freedom rate and a more favorable safety profile than TPM in this population of Korean patients with focal seizures. PMID: 31195326 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31195326?dopt=Abstract

Source: Epilepsy and Behaviour - June 9, 2019 Category: Neurology Authors: Lee SK, Lee SA, Kim DW, Loesch C, Pelgrims B, Osakabe T, Lee B, N01353 study group Tags: Epilepsy Behav Source Type: research